On April 30, 2009, a 38-year-old woman underwent ICL implantation in both eyes for correction of a refractive error. Twelve years later, slit lamp examination and gonioscopy confirmed the presence of an open-angle structure in the left eye, with no other abnormalities in the anterior eye segment (including the cornea, trabecular meshwork, and iris). Furthermore, glaucomatous changes in the optic disc and retinal nerve fiber layer as well as visual field defects were observed. Thus, she was diagnosed with open-angle glaucoma of the left eye. The patient had no history of any other ophthalmic diseases, systemic diseases (such as systemic hypertension or diabetes mellitus), and treatments (except for a bilateral laser iridotomy for ICL implantation). At the time of glaucoma diagnosis, the best corrected visual acuity (BCVA) was 20/20, and the intraocular pressure in both eyes (determined using a Goldmann applanation tonometer) was 15 mmHg. Furthermore, swept source optical coherence tomography (SS-OCT) revealed a normal macula in the left eye. Considering that topical anti-glaucoma medications should only be administered to one eye in young patients, an OMDI ophthalmic solution was prescribed. However, the patient complained of visual discomfort in the left eye following approximately 9 months of solution usage, although the BCVA did not deteriorate. The presence of CME was confirmed using SS-OCT. The OMDI solution was discontinued immediately, and topical bromfenac sodium hydrate was administered to the left eye (twice daily) to improve the CME instead. One month after OMDI discontinuation, SS-OCT revealed improvement in the CME. The patient’s visual discomfort disappeared 2 months later with normalization of the macula. After confirming the absence of CME recurrence through an additional 1-month follow-up, the patient started using a topical beta blocker for the treatment of glaucoma in the left eye.